Keywords: mgi, ovarian, cancer, pharma, started, its, third

MGI 114 For Ovarian Cancer

Article | 02 December 1998

Print This

MGI Pharma has started its third Phase II trial of MGI 114, anacylfulvene cytotoxic, in patients with advanced ovarian cancer who ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in